In the phase 2 DALY 2-EU trial, zamto-cel prolonged median event-free survival vs R-GemOx in transplant-ineligible relapsed/refractory large B-cell lymphoma.
News|Podcasts|August 29, 2021
OncView™ Podcast: Updates in Therapies for Relapsed/Refractory Follicular Lymphoma
Author(s)Matthew Fowler, Javier L. Munoz, MD, MS, FACP
This special episode of “Oncology Peer Review On-The-Go” includes a discussion on relapsed/refractory follicular lymphoma with Javier Munoz, MD, MS, FACP.
Advertisement
As part of its OncView™ video series, CancerNetwork® spoke with Javier Munoz, MD, MS, FACP, from the Mayo Clinic in Phoenix, Arizona, about updates in therapies for relapsed/refractory (R/R) follicular lymphoma (FL).
In the video series, Javier Munoz, MD, MS, FACP, discussed the following:
Current Treatment Options for Relapsed/Refractory Follicular Lymphoma Factors in Choosing R/R FL Treatments Treatment Options for Third-Line R/R FL Use of Tazemetostat for R/R FL Changes in Sequencing of R/R FL Therapies
To watch more videos in CancerNetwork®’s OncView™ series, visit
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.
Advertisement
Related to this article
Rocbrutinib plus R-CHOP yielded a 100% ORR and an 86.7% CR rate in 15 patients with untreated non-GCB DLBCL, warranting randomized evaluation.
Grade 3/4 neurotoxicity in patients prompted a partial clinical hold on the PALISADES-1 and PALISADES-2 trials of KITE-753 in large B-cell lymphoma.
In a phase 2 trial, orelabrutinib plus sintilimab yielded a 60.7% overall response rate in relapsed/refractory primary CNS lymphoma.
Adam C. Olson, MD, MSc-GH, discussed the infrastructure, training, and shared decision-making behind building a prostate HDR brachytherapy program.
In HypoMast-IMNI, 16-fraction PMRT with internal mammary node irradiation matched conventional RT for locoregional control with less grade 3 skin toxicity.
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
Tyler J. Wilhite, MD, discussed coordinating with rheumatology, orthopedic surgery, and primary care when treating patients with osteoarthritis with low-dose radiation therapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
AI-Measured Tumor Volume on PSMA PET-CT Linked With Survival in Prostate Cancer
2
Mapping Practical Steps to Expand CAR T-Cell Access in Multiple Myeloma
3
Scaling Low-Dose Radiation Therapy for Osteoarthritis Across a Network
4
Surgery Correlates With Better Survival Vs SABR in Early-Stage NSCLC
5